Evidence map›Paper›PMID 27597932›Full record

ArticleFrontiers in oncology2016

A Time-Based and Intratumoral Proteomic Assessment of a Recurrent Glioblastoma Multiforme.

Priscila F de Aquino, Paulo Costa Carvalho, Fábio C S Nogueira, Clovis Orlando da Fonseca, Júlio Cesar Thomé de Souza Silva, Maria da Gloria da Costa Carvalho, Gilberto B Domont, Nilson I T Zanchin, Juliana de Saldanha da Gama Fischer

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Adhesion to aggression: unravelling sLeClinical & experimental metastasis · 2025
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Priscila F de AquinoLaboratory of Microbial Diversity from Amazon with Importance for Health, Instituto Leônidas e Maria Deane, Fiocruz , Manaus, Amazonas , Brazil.
Paulo Costa CarvalhoLaboratory for Proteomics and Protein Engineering, Carlos Chagas Institute, Fiocruz, Curitiba, Paraná, Brazil; Laboratory of Toxinology, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.
Fábio C S NogueiraLaboratory for Protein Chemistry, Chemistry Institute, Federal University of Rio de Janeiro , Rio de Janeiro , Brazil.
Clovis Orlando da FonsecaDepartment of General and Specialized Surgery, Antonio Pedro University Hospital, Fluminense Federal University , Rio de Janeiro , Brazil.
Júlio Cesar Thomé de Souza SilvaDepartment of Neurosurgery, Ipanema Federal Hospital , Rio de Janeiro , Brazil.
Maria da Gloria da Costa CarvalhoLaboratory of Molecular Pathology, Department of Pathology, University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro , Rio de Janeiro , Brazil.
Gilberto B DomontLaboratory for Protein Chemistry, Chemistry Institute, Federal University of Rio de Janeiro , Rio de Janeiro , Brazil.
Nilson I T ZanchinLaboratory for Proteomics and Protein Engineering, Carlos Chagas Institute, Fiocruz , Curitiba, Paraná , Brazil.
Juliana de Saldanha da Gama FischerLaboratory for Proteomics and Protein Engineering, Carlos Chagas Institute, Fiocruz , Curitiba, Paraná , Brazil.
Universidade Federal do Rio de Janeiro · BRFundação Carlos Chagas · BRFundação Oswaldo Cruz · BRUniversidade Federal Fluminense · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumors consist of cells in different stages of transformation with molecular and cellular heterogeneity. By far, heterogeneity is the hallmark of glioblastoma multiforme (GBM), the most malignant and aggressive type of glioma. Most proteomic studies aim in comparing tumors from different patients, but here we dive into exploring the intratumoral proteome diversity of a single GBM. For this, we profiled tumor fragments from the profound region of the same patient's GBM but obtained from two surgeries a year's time apart. Our analysis also included GBM's fragments from different anatomical regions. Our quantitative proteomic strategy employed 4-plex iTRAQ peptide labeling followed by a four-step strong cation chromatographic separation; each fraction was then analyzed by reversed-phase nano-chromatography coupled on-line with an Orbitrap-Velos mass spectrometer. Unsupervised clustering grouped the proteomic profiles into four major distinct groups and showed that most changes were related to the tumor's anatomical region. Nevertheless, we report differentially abundant proteins from GBM's fragments of the same region but obtained 1 year apart. We discuss several key proteins (e.g., S100A9) and enriched pathways linked with GBM such as the Ras pathway, RHO GTPases activate PKNs, and those related to apoptosis, to name a few. As far as we know, this is the only report that compares GBM fragments proteomic profiles from the same patient. Ultimately, our results fuel the forefront of scientific discussion on the importance in exploring the richness of subproteomes within a single tissue sample for a better understanding of the disease, as each tumor is unique.

Indexed as

glioblastoma multiformeiTRAQmolecular heterogeneityquantitative proteomics

Identifiers

PMID27597932
PMCPMC4992702
OpenAlexW2515969009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.